Most Read Articles
Elvira Manzano, 06 May 2021
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Jairia Dela Cruz, 11 Aug 2020
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.
Elaine Soliven, 16 May 2021
Treatment with either low-dose (LD) or high-dose (HD) secukinumab showed continued improvement in PASI* and IGA** responses up to 24 weeks in children and adolescents with moderate-to-severe plaque psoriasis, according to updated results of a trial presented at PAS 2021.

Add-on tacrolimus provides short-term survival gains in PM/DM-interstitial pneumonia

21 Oct 2019

Initial treatment with tacrolimus and glucocorticoids (GCs) appears to improve short-term mortality in polymyositis (PM)/dermatomyositis (DM)-interstitial pneumonia patients, according to a recent study.

A total of 25 patients (mean age, 55.4 years; 76 percent female) received initial combination treatment with tacrolimus (0.075 mg/kg/day, adjusted for the target whole-blood trough levels between 5 and 10 ng/ml) and glucocorticoids (0.6–1.0 mg/kg/day of prednisolone followed by a slow taper) for 52 weeks.

The primary outcome of overall survival at 52 weeks was 88.0 percent (95 percent CI, 67.3–96.0 percent). Progression-free survival rate was 76.4 percent (51.8–89.5 percent).

Whole-blood tacrolimus trough levels were preserved within the targeted range of 5 and 10 ng/ml throughout the study period (average, 6.6 ng/ml), with an average daily dose of 3.81 mg/day (0.072 mg/kg/day).

The safety profile of the combination treatment was consistent with the known adverse event (AE) profile of tacrolimus and high-dose GCs individually. A total of 11 patients (44 percent) developed serious adverse events, which included four opportunistic infections.

In total, there were 475 AEs recorded, of which 357 (75.2 percent) were deemed possibly, probably or definitely associated with tacrolimus or GCs by treating physicians.

The current prospective clinical investigation was the first to be conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of PM/DM-interstitial pneumonia.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 06 May 2021
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Jairia Dela Cruz, 11 Aug 2020
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.
Elaine Soliven, 16 May 2021
Treatment with either low-dose (LD) or high-dose (HD) secukinumab showed continued improvement in PASI* and IGA** responses up to 24 weeks in children and adolescents with moderate-to-severe plaque psoriasis, according to updated results of a trial presented at PAS 2021.